Full View

Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar… - Circulation, 2022 - Am Heart Assoc
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …
被引用次数：56 相关文章

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar… - 2022 - pubmed.ncbi.nlm.nih.gov
Background The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet
therapy in critically ill COVID-19 patients remain uncertain. Methods COVID-PACT …

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT.

EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar… - Circulation, 2022 - europepmc.org
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically-ill COVID-19 patients remains uncertain. Methods: COVID …

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes, JM Connors… - …, 2022 - ingentaconnect.com
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes, JM Connors… - …, 2022 - einstein.elsevierpure.com
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes… - …, 2022 - providence.elsevierpure.com
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-pact.

EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar… - 2022 - cabidigitallibrary.org
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar… - Circulation, 2022 - profiles.wustl.edu
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …
[HTML] nih.gov

[HTML][HTML] Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

EA Bohula, DD Berg, MS Lopes, JM Connors, I Babar… - Circulation, 2022 - ncbi.nlm.nih.gov
Background: The efficacy and safety of prophylactic full-dose anticoagulation and
antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID …